SCHEMBL23148015

SCHEMBL23148015

Fc1cncc2[nH]ccc12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.43
BRD4 O60885 1/20 0.41
GPR84 Q9NQS5 1/20 0.39
IGF1R P08069 1/20 0.37
CDK2 P24941 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
PIK3C3 Q8NEB9 2/20 0.35
PIK3CD O00329 1/20 0.35
TRPA1 O75762 3/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
AHR P35869 3/20 0.33
NFATC1 O95644 2/20 0.33
DYRK1A Q13627 2/20 0.33
GSK3B P49841 1/20 0.32
POLB P06746 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TGFBR1 P36897 1/20 0.31
TGFBR2 P37173 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1019760 0.74 NFATC1 (0.44) BRD4IGF1RCDK2DYRK1BPIK3C3
SCHEMBL30578263 0.74 BRD4 (0.41) BRD4IGF1RCDK2DYRK1BPIK3C3
SCHEMBL30554075 0.74 NFATC1 (0.44) BRD4IGF1RCDK2DYRK1BPIK3C3
SCHEMBL23937722 0.74 BRD4 (0.45) NUDT1BRD4IGF1RCDK2DYRK1B
SCHEMBL529739 0.74 AHR (0.52) BRD4IGF1RCDK2DYRK1BPIK3C3
SCHEMBL15926855 0.74 BRD4 (0.41) BRD4GPR84IGF1RCDK2DYRK1B
SCHEMBL30368744 0.74 BRD4 (0.45) NUDT1BRD4IGF1RCDK2DYRK1B
SCHEMBL2628872 0.74 BRD4 (0.41) BRD4IGF1RCDK2DYRK1BPIK3C3
SCHEMBL2619221 0.74 BRD4 (0.45) BRD4IGF1RCDK2DYRK1BPIK3C3
SCHEMBL25336148 0.74 BRD4 (0.39) BRD4IGF1RCDK2DYRK1BPIK3C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616682-B2 1-H-pyrrolo[2,3-c]pyridine compounds ACERTA PHARMA B.V. (NL) 2026-05-05 US disclosed
EP-4688776-A1 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN Acerta Pharma B.V. (NL) 2026-02-11 EP disclosed
US-20250360112-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS ACERTA PHARMA BV (NL) 2025-11-27 US disclosed
CN-119490487-A Polysubstituted tetrahydrocarbazole compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2025-02-21 CN disclosed
US-20240335431-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS ACERTA PHARMA B.V. (NL) 2024-10-10 US disclosed
WO-2024201240-A1 1-H-PYRROLO[2,3-C]PYRIDINE COMPOUNDS ACTING AGAINST CANCER VIA AGONISM OF MENIN ACERTA PHARMA B.V. (NL) 2024-10-03 WO disclosed
US-20230250096-A1 SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-08-10 US disclosed
US-20230002372-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) 2023-01-05 US disclosed
US-20230002372-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) 2023-01-05 US disclosed
EP-4034108-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS The Global Alliance for TB Drug Development, Inc. (US) 2022-08-03 EP disclosed
CN-114746090-A Azaindole carboxamide compounds for the treatment of mycobacterial infections 结核病药物开发全球联盟公司 2022-07-12 CN disclosed
WO-2021062316-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2021-04-01 WO disclosed
WO-2021062316-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) 2021-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250096-A1 SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES MLLT1, BMI1, MEN1 NUDT1 2451/4885BRD4 59/4885GPR84 4226/4885
US-12616682-B2 1-H-pyrrolo[2,3-c]pyridine compounds MEN1, PKD1, PKD2 NUDT1 2807/4885BRD4 1213/4885GPR84 4400/4885
US-20230002372-A1 AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS AZI2, AADAC, TPMT NUDT1 711/4885BRD4 38/4885GPR84 1646/4885
US-20240335431-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS MEN1, PKD1, ADCYAP1R1 NUDT1 1393/4885BRD4 1432/4885GPR84 4133/4885
US-20250360112-A1 1-H-PYRROLO[2,3-c]PYRIDINE COMPOUNDS MEN1, PKD1, ADCYAP1R1 NUDT1 1393/4885BRD4 1432/4885GPR84 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.